Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 5, 2017 - Issue 1
Journal homepage
1,377
Views
8
CrossRef citations to date
0
Altmetric
Original Research Article

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

Luigi R. CodecasaRegional TB Reference Centre, Villa Marelli Institute/ASST Niguarda Ca’ Granda, Milano, ItalyCorrespondence[email protected]
View further author information
,
Mondher ToumiFaculty of Medicine, Public Health Department, Aix-Marseille University, Marseille, FranceView further author information
,
Anna D’AusilioCreativ-Ceutical, Milano, ItalyView further author information
,
Andrea AielloCreativ-Ceutical, Milano, ItalyView further author information
,
Francesco DameleJanssen-Cilag, Cologno Monzese, ItalyView further author information
,
Roberta TerminiJanssen-Cilag, Cologno Monzese, ItalyView further author information
,
Alessia UgliettiJanssen-Cilag, Cologno Monzese, ItalyView further author information
,
Robert HettleParexel International, London, UKView further author information
,
Giorgio GrazianoPost-graduate Residency School in Hygiene and Preventive Medicine, University of Palermo, Palermo, ItalyView further author information
&
Saverio De LorenzoE. Morelli Hospital ASST, Reference Center for MDR-TB and HIV-TB, Sondalo, ItalyView further author information
 show all
Article: 1283105 | Received 07 Nov 2016, Accepted 22 Dec 2016, Published online: 17 Feb 2017

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ginenus Fekadu, Jiaqi Yao & Joyce H.S. You. (2021) A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 897-910.
Read now

Articles from other publishers (7)

N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova & N. P. Doktorova. (2023) Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 16:2, pages 162-175.
Crossref
А. V. Kukurika. (2022) Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15:3, pages 353-362.
Crossref
Joo-Young Byun, Hye-Lin Kim, Eui-Kyung Lee & Sun-Hong Kwon. (2021) A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments. Frontiers in Pharmacology 12.
Crossref
N. Yu. Nikolenko, D. А. Kudlay & N. P. Doktorova. (2021) Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 14:2, pages 235-248.
Crossref
Evita Sari, Neily Zakiyah, Prayudi Santoso & Melisa I. Barliana. (2021) Cost-Effectiveness of Bedaquiline in Multidrug Resistant Tuberculosis: A Review. The Open Public Health Journal 14:1, pages 282-290.
Crossref
Steven Simoens & Isabel Spriet. (2021) Guidance for Demonstrating the Societal Value of new Antibiotics. Frontiers in Pharmacology 11.
Crossref
Kathryn Schnippel, Cynthia Firnhaber, Francesca Conradie, Norbert Ndjeka & Edina Sinanovic. (2017) Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Applied Health Economics and Health Policy 16:1, pages 43-54.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.